EVOTAZ Drug Patent Profile
✉ Email this page to a colleague
When do Evotaz patents expire, and when can generic versions of Evotaz launch?
Evotaz is a drug marketed by Bristol and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and ninety-five patent family members in forty countries.
The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the atazanavir sulfate; cobicistat profile page.
DrugPatentWatch® Generic Entry Outlook for Evotaz
Evotaz was eligible for patent challenges on August 27, 2016.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 6, 2032. This may change due to patent challenges or generic licensing.
There have been eight patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for EVOTAZ
| International Patents: | 295 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 5 |
| Patent Applications: | 98 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for EVOTAZ |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for EVOTAZ |
| What excipients (inactive ingredients) are in EVOTAZ? | EVOTAZ excipients list |
| DailyMed Link: | EVOTAZ at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for EVOTAZ
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for EVOTAZ
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Gilead Sciences | Phase 3 |
| St Stephens Aids Trust | Phase 1 |
| Bristol-Myers Squibb | Phase 1 |
Pharmacology for EVOTAZ
Anatomical Therapeutic Chemical (ATC) Classes for EVOTAZ
Paragraph IV (Patent) Challenges for EVOTAZ
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| EVOTAZ | Tablets | atazanavir sulfate; cobicistat | 300 mg/150 mg | 206353 | 1 | 2017-09-13 |
US Patents and Regulatory Information for EVOTAZ
EVOTAZ is protected by two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of EVOTAZ is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting EVOTAZ
Use of solid carrier particles to improve the processability of a pharmaceutical agent
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Modulators of pharmacokinetic properties of therapeutics
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol | EVOTAZ | atazanavir sulfate; cobicistat | TABLET;ORAL | 206353-001 | Jan 29, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Bristol | EVOTAZ | atazanavir sulfate; cobicistat | TABLET;ORAL | 206353-001 | Jan 29, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EVOTAZ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bristol | EVOTAZ | atazanavir sulfate; cobicistat | TABLET;ORAL | 206353-001 | Jan 29, 2015 | ⤷ Sign Up | ⤷ Sign Up |
| Bristol | EVOTAZ | atazanavir sulfate; cobicistat | TABLET;ORAL | 206353-001 | Jan 29, 2015 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for EVOTAZ
When does loss-of-exclusivity occur for EVOTAZ?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
African Regional IP Organization (ARIPO)
Patent: 89
Estimated Expiration: ⤷ Sign Up
Patent: 50
Estimated Expiration: ⤷ Sign Up
Argentina
Patent: 5369
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 09242451
Estimated Expiration: ⤷ Sign Up
Patent: 10210598
Estimated Expiration: ⤷ Sign Up
Patent: 14221210
Estimated Expiration: ⤷ Sign Up
Patent: 15200637
Estimated Expiration: ⤷ Sign Up
Patent: 16250470
Estimated Expiration: ⤷ Sign Up
Patent: 17201473
Estimated Expiration: ⤷ Sign Up
Patent: 18267573
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0911871
Estimated Expiration: ⤷ Sign Up
Patent: 1008664
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 20856
Estimated Expiration: ⤷ Sign Up
Patent: 50521
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 11001885
Estimated Expiration: ⤷ Sign Up
China
Patent: 2123700
Estimated Expiration: ⤷ Sign Up
Patent: 2307573
Estimated Expiration: ⤷ Sign Up
Patent: 3479584
Estimated Expiration: ⤷ Sign Up
Patent: 4940937
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 21225
Estimated Expiration: ⤷ Sign Up
Patent: 00187
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0151009
Estimated Expiration: ⤷ Sign Up
Patent: 0151357
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 16852
Estimated Expiration: ⤷ Sign Up
Patent: 17067
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 96633
Estimated Expiration: ⤷ Sign Up
Patent: 93485
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 10010636
Estimated Expiration: ⤷ Sign Up
Patent: 11011307
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 1313
Estimated Expiration: ⤷ Sign Up
Patent: 2950
Estimated Expiration: ⤷ Sign Up
Patent: 0123
Estimated Expiration: ⤷ Sign Up
Patent: 1071173
Estimated Expiration: ⤷ Sign Up
Patent: 1190125
Estimated Expiration: ⤷ Sign Up
Patent: 1491658
Estimated Expiration: ⤷ Sign Up
Patent: 1591353
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 96633
Estimated Expiration: ⤷ Sign Up
Patent: 93485
Estimated Expiration: ⤷ Sign Up
Patent: 06032
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 53670
Estimated Expiration: ⤷ Sign Up
Patent: 64737
Estimated Expiration: ⤷ Sign Up
Patent: 15679
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 25822
Estimated Expiration: ⤷ Sign Up
Patent: 26380
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 8614
Estimated Expiration: ⤷ Sign Up
Patent: 4227
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 11242
Estimated Expiration: ⤷ Sign Up
Patent: 22213
Estimated Expiration: ⤷ Sign Up
Patent: 11927
Estimated Expiration: ⤷ Sign Up
Patent: 25171
Estimated Expiration: ⤷ Sign Up
Patent: 11522790
Estimated Expiration: ⤷ Sign Up
Patent: 12517432
Estimated Expiration: ⤷ Sign Up
Patent: 14012741
Estimated Expiration: ⤷ Sign Up
Patent: 14221845
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 2377
Estimated Expiration: ⤷ Sign Up
Patent: 10011963
Estimated Expiration: ⤷ Sign Up
Patent: 11008289
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 8978
Estimated Expiration: ⤷ Sign Up
Patent: 4214
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 110994
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 96633
Estimated Expiration: ⤷ Sign Up
Patent: 93485
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 96633
Estimated Expiration: ⤷ Sign Up
Patent: 93485
Estimated Expiration: ⤷ Sign Up
San Marino
Patent: 01500266
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 3544
Estimated Expiration: ⤷ Sign Up
Patent: 0618
Estimated Expiration: ⤷ Sign Up
Patent: 14007744
Estimated Expiration: ⤷ Sign Up
Patent: 201609006W
Estimated Expiration: ⤷ Sign Up
Patent: 201706215U
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 96633
Estimated Expiration: ⤷ Sign Up
Patent: 93485
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1008007
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1645759
Estimated Expiration: ⤷ Sign Up
Patent: 1659971
Estimated Expiration: ⤷ Sign Up
Patent: 1738325
Estimated Expiration: ⤷ Sign Up
Patent: 1784647
Estimated Expiration: ⤷ Sign Up
Patent: 110015581
Estimated Expiration: ⤷ Sign Up
Patent: 110122729
Estimated Expiration: ⤷ Sign Up
Patent: 160093100
Estimated Expiration: ⤷ Sign Up
Patent: 160114728
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 48886
Estimated Expiration: ⤷ Sign Up
Patent: 53897
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 44367
Estimated Expiration: ⤷ Sign Up
Patent: 1040142
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 1193
Estimated Expiration: ⤷ Sign Up
Patent: 3224
Estimated Expiration: ⤷ Sign Up
Uruguay
Patent: 424
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering EVOTAZ around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Taiwan | 200909422 | Modulators of pharmacokinetic properties of therapeutics | ⤷ Sign Up |
| European Patent Office | 2118082 | MODULATEURS DE PROPRIÉTÉS PHARMACOCINÉTIQUES DE PRODUITS THÉRAPEUTIQUES (MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS) | ⤷ Sign Up |
| Taiwan | 409125 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for EVOTAZ
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2487162 | CA 2017 00002 | Denmark | ⤷ Sign Up | PRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF OG DARUNAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, ISAER DARUNAVIRETHANOLAT; REG. NO/DATE: EU/1/14/967/001 20141121 |
| 2049506 | C20150046 | Estonia | ⤷ Sign Up | PRODUCT NAME: KOBITSISTAAT; AUTHORISATION NO.: EMA/CHMP/596576/2017, AUTORISATION DATE: 20170914 |
| 2049506 | 132015000080648 | Italy | ⤷ Sign Up | PRODUCT NAME: COBICISTAT O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(STRIBILD); AUTHORISATION NUMBER(S) AND DATE(S): C(2013)3210, 20130527 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
